These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10950233)

  • 41. A pharmacokinetic simulation tool for inhaled corticosteroids.
    Weber B; Hochhaus G
    AAPS J; 2013 Jan; 15(1):159-71. PubMed ID: 23139018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
    Kempsford R; Allen A; Bal J; Rubin D; Tombs L
    Br J Clin Pharmacol; 2013 Jun; 75(6):1478-87. PubMed ID: 23116485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adrenal crisis caused by inhaled fluticasone in an adolescent with cystic fibrosis and advanced hepatopathy: a case report.
    Denne C; Vogl-Voswinckel AE; Gruebl A; Burdach S
    Case Rep Pulmonol; 2012; 2012():913574. PubMed ID: 23056987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy.
    Williamson PA; Short PM; Vaidyanathan S; Lipworth BJ
    Br J Clin Pharmacol; 2013 Jan; 75(1):93-102. PubMed ID: 22568828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.
    Blake K; Mehta R; Spencer T; Kunka RL; Hendeles L
    Eur Respir J; 2012 Jan; 39(1):97-103. PubMed ID: 21933835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of inhaled corticosteroids in the management of cystic fibrosis.
    Ross KR; Chmiel JF; Konstan MW
    Paediatr Drugs; 2009; 11(2):101-13. PubMed ID: 19301932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction.
    Mortimer KJ; Tattersfield AE; Tang Y; Wu K; Lewis S; Hochhaus G; Harrison TW
    Br J Clin Pharmacol; 2007 Oct; 64(4):439-44. PubMed ID: 17711540
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations.
    Gulliver T; Morton R; Eid N
    Paediatr Drugs; 2007; 9(3):185-94. PubMed ID: 17523699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
    Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
    Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.
    Mortimer KJ; Harrison TW; Tang Y; Wu K; Lewis S; Sahasranaman S; Hochhaus G; Tattersfield AE
    Br J Clin Pharmacol; 2006 Oct; 62(4):412-9. PubMed ID: 16995862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone.
    Paton J; Jardine E; McNeill E; Beaton S; Galloway P; Young D; Donaldson M
    Arch Dis Child; 2006 Oct; 91(10):808-13. PubMed ID: 16556614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How has research in the last five years changed my clinical practice?
    Bush A
    Arch Dis Child; 2005 Aug; 90(8):832-6. PubMed ID: 16040883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?
    Man SF; Sin DD
    Drugs; 2005; 65(5):579-91. PubMed ID: 15748094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review.
    Kankaanranta H; Lahdensuo A; Moilanen E; Barnes PJ
    Respir Res; 2004 Oct; 5(1):17. PubMed ID: 15509300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease.
    Lee DK; Lipworth BJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):388-92. PubMed ID: 15025735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of the newer inhaled corticosteroids in childhood asthma.
    Randell TL; Donaghue KC; Ambler GR; Cowell CT; Fitzgerald DA; van Asperen PP
    Paediatr Drugs; 2003; 5(7):481-504. PubMed ID: 12837120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.
    Singh SD; Whale C; Houghton N; Daley-Yates P; Kirby SM; Woodcock AA
    Br J Clin Pharmacol; 2003 Apr; 55(4):375-81. PubMed ID: 12680886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects.
    Harrison TW; Tattersfield AE
    Thorax; 2003 Mar; 58(3):258-60. PubMed ID: 12612308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adrenal insufficiency after treatment with fluticasone. Second line controller treatment might have been tried.
    Lipworth BJ
    BMJ; 2002 Oct; 325(7368):836; author reply 836. PubMed ID: 12376451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.